Relating To Viral Hepatitis.
HB1112 would create a new hepatitis prevention program within the Hawaii Department of Health to reduce illness and deaths from hepatitis B and hepatitis C. The bill directs the department to develop and administer a statewide program focused on awareness and education, improving access to services, promoting health equity, and collecting and reporting data. It also requires a comprehensive statewide prevention plan that includes screening and support for people with hepatitis to access care and treatment, and allows the department to coordinate with other agencies, health care providers, insurers, and community stakeholders.
The bill also updates existing law on prenatal hepatitis B screening by preserving the department’s authority to adopt rules for screening pregnant women and follow-up for newborns of hepatitis B carrier mothers, while removing an outdated provision about providing medications to indigent and medically indigent carrier mothers. In addition, it repeals an obsolete statute concerning implied warranties for blood products and hepatitis, reflecting changes in medical science and blood safety practices. The measure includes an unspecified general fund appropriation for fiscal years 2025-2026 and 2026-2027 and authorizes new positions in the Department of Health to support implementation.
The bill’s impact on state law would be to add new statutory authority in chapter 325 for hepatitis prevention, screening, education, and treatment support, while also revising and repealing older hepatitis-related provisions. It would expand the Department of Health’s role in coordinating public health responses to viral hepatitis and formally embed prevention planning and data-driven intervention into state law. The appropriation language would also create a funding mechanism for staffing and program operations, although the dollar amount is left blank in the text provided.
The general sentiment reflected in the bill findings is strongly supportive of expanded state action. The findings emphasize that hepatitis B and C are linked to higher mortality in Hawaii, that disparities affect Asian and Pacific Islander residents, and that effective prevention and treatment tools already exist but are underfunded. The bill frames the issue as a public health gap that the state should address through coordinated intervention, education, and equitable access to care.
There is little explicit opposition or debate in the materials provided, but the main points of potential contention are the need for new state spending, the creation of new Department of Health positions, and the scope of the department’s responsibilities. The bill also appears to be partly technical in nature, since it removes an outdated blood-transfusion provision and modifies prenatal screening language. No committee testimony or recorded votes were provided, so no direct evidence of disagreement is available.
HB1112 would amend chapter 325, Hawaii Revised Statutes, by adding new provisions authorizing and directing the Department of Health to establish a hepatitis prevention program, develop statewide education and prevention plans, support screening and treatment access, and coordinate with outside partners. It would also revise section 325-92 on prenatal hepatitis B screening and repeal section 325-91 concerning blood transfusions and hepatitis. The bill further appropriates general funds for program implementation and staffing, thereby creating a new state-funded public health initiative focused on hepatitis B and C.
The bill is presented in a strongly supportive, public-health-oriented tone. Its findings stress elevated hepatitis-related mortality in Hawaii, disparities affecting Asian and Pacific Islander residents, and the availability of effective prevention and treatment tools that are not being fully deployed. The overall sentiment is that the state should take a more active role through funding, coordination, education, screening, and treatment support. No committee discussion or votes were provided, so there is no recorded opposition or amendment debate to assess.
The main likely points of contention are fiscal and administrative rather than ideological: the bill requires an unspecified general fund appropriation and new Department of Health positions, which may raise budget concerns. Some may also question the breadth of the department’s new responsibilities or the need to codify program priorities such as health equity and social determinants of health. The repeal of the outdated blood-transfusion statute and the narrowing of prenatal hepatitis language appear technical and are unlikely to be controversial, but they do reflect a broader modernization of the law.